The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 42 | — | 20.3x | Near average | |
Growth | 50 | 39.0% | 5.6% | Near average | |
Quality | 40 | -64.6% | 7.6% | Near average | |
Safety | 65 | 1.4x | 0.4x | Near average | |
Capital Return | 41 | — | 2.15% | Near average | |
Momentum | 98 | — | — | Above average | |
Sentiment | 35 | — | — | Near average |
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Tango Therapeutics, Inc. (NASDAQ: TNGX) is a clinical-stage biopharmaceutical company focused primarily on the discovery and development of targeted cancer therapies using the principle of synthetic lethality to target genetic vulnerabilities in cancer cells. The company generates its revenue mainly through collaboration agreements and strategic drug development partnerships, with revenue for the trailing twelve months (TTM) reaching approximately $57.0 million, compared to $62.4 million in fiscal year 2025.
On the financial front and recent performance, the company recorded a net loss of $45.5 million in the first quarter of 2026, with a loss per share of $0.32. This follows the company achieving positive net income of $15.9 million in the third quarter of 2025 (with earnings per share of $0.13), before results declined in the fourth quarter and fiscal year 2025 to record a net loss of $101.6 million and a loss per share of $0.87. These fluctuations reflect the nature of biotechnology companies that rely on the timing of revenue recognition from partnerships and rising clinical research and development costs.
Tango Therapeutics stock is currently trading at $30.93, which lies within the 52-week range spanning between $3.77 and $32.5. The current trading price is below the average analyst target price of $39.88, with optimistic estimates reaching a high of $69 and more conservative ones at a low of $24, amid a general consensus among analysts recommending a 'Buy'.
The significant 34% increase in the stock price on June 8, 2026, is due to Tango Therapeutics' announcement of highly promising clinical results for its innovative targeted treatment for advanced pancreatic cancer. These results demonstrated the capability of the company's development platform to target intractable tumors, which boosted investor and financial institution confidence in the scientific and commercial value of the company's pipeline.
The company's recent financial statements show fluctuations depending on development stages; the company recorded a net loss of $45.5 million in the first quarter of 2026 and a loss of $101.6 million for the full fiscal year 2025. However, in the third quarter of 2025, the company managed to achieve a positive net income of $15.9 million due to partnership revenues, and its revenue for the trailing twelve months reached $57.0 million.
The consensus of analysts currently rates TNGX stock as a 'Buy', with an average target price of $39.88. The range of analyst forecasts is wide, with the high target for the stock at $69, while the low forecast is $24, meaning that the current price of $30.93 is trading below the target average.
Automated analysis for informational purposes only — not investment advice.
Yes, recent data indicates a strong sell signal from insiders (strong_sell) at Tango Therapeutics, with net sales over the past three months totaling approximately $1.2 million. Four sales were recorded by insiders without any new purchases being made, and the last of those recorded transactions was on June 1, 2026.